A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703
Nobumichi Matsubara(Miyagi Prefectural Hospital Organization), Toshihiro Nukiwa(Tohoku University), Naoto Morikawa(Tohoku University), Masashi Tanaka(Tohoku University), Akira Inoue(Tohoku University Hospital), Osamu Ishimoto(Sendai Kousei Hospital), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Tomohiro Sakakibara(Tohoku University Hospital), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 12
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953